Contineum Therapeutics, Inc. financial data

Symbol
CTNM on Nasdaq
Location
San Diego, CA
Fiscal year end
31 December
Latest financial report
05 Mar 2026

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2547% % -14%
Debt-to-equity 6.4% % 13%
Return On Equity -30% % 2.1%
Return On Assets -28% % -29%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 23,099,173 shares
Common Stock, Shares, Outstanding 2,384,426 shares
Entity Public Float $102,100,000 USD -71%
Common Stock, Value, Issued $2,000 USD
Weighted Average Number of Shares Outstanding, Basic 27,700,855 shares 43%
Weighted Average Number of Shares Outstanding, Diluted 19,352,859 shares 470%

Income Statement

Label TTM Value / Value Unit Change %
Revenue from Contract with Customer, Excluding Assessed Tax $0 USD
Research and Development Expense $51,522,000 USD 34%
General and Administrative Expense $16,537,000 USD 33%
Operating Income (Loss) $68,059,000 USD -34%
Nonoperating Income (Expense) $8,081,000 USD -6.4%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $42,258,000 USD -282%
Income Tax Expense (Benefit) $0 USD -100%
Net Income (Loss) Attributable to Parent $59,978,000 USD -42%
Earnings Per Share, Basic -2.17 USD/shares 0.46%
Earnings Per Share, Diluted -0.4 USD/shares 85%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $75,603,000 USD 245%
Marketable Securities, Current $187,293,000 USD 2.4%
Cash, Cash Equivalents, and Short-term Investments $262,900,000 USD 28%
Assets, Current $267,917,000 USD 30%
Property, Plant and Equipment, Net $830,000 USD -16%
Operating Lease, Right-of-Use Asset $7,639,000 USD 40%
Other Assets, Noncurrent $256,000 USD 8433%
Assets $276,642,000 USD 30%
Accounts Payable, Current $1,016,000 USD -44%
Employee-related Liabilities, Current $4,796,000 USD 44%
Accrued Liabilities, Current $6,387,000 USD -4.8%
Liabilities, Current $9,744,000 USD -2.3%
Operating Lease, Liability, Noncurrent $5,909,000 USD 23%
Other Liabilities, Noncurrent $0 USD -100%
Liabilities $15,653,000 USD 5.9%
Accumulated Other Comprehensive Income (Loss), Net of Tax $260,000 USD 266%
Retained Earnings (Accumulated Deficit) $177,380,000 USD -51%
Stockholders' Equity Attributable to Parent $260,989,000 USD 32%
Liabilities and Equity $276,642,000 USD 30%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $14,412,000 USD -81%
Net Cash Provided by (Used in) Financing Activities $24,000,000 USD
Net Cash Provided by (Used in) Investing Activities $14,915,000 USD 71%
Common Stock, Shares Authorized 39,630,511 shares 0%
Common Stock, Shares, Issued 2,384,426 shares
Common Stock, Par or Stated Value Per Share 0.001 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $527,000 USD -29%
Deferred Tax Assets, Valuation Allowance $47,960,000 USD 35%
Deferred Tax Assets, Gross $49,698,000 USD 35%
Operating Lease, Liability $8,250,000 USD 32%
Payments to Acquire Property, Plant, and Equipment $47,000 USD -68%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $59,789,000 USD -41%
Property, Plant and Equipment, Gross $2,793,000 USD 3.2%
Operating Lease, Liability, Current $2,341,000 USD 61%
Deferred Tax Assets, Operating Loss Carryforwards $33,123,000 USD 129%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10,000,000 shares 0%
Unrecognized Tax Benefits $3,564,000 USD 15%
Operating Lease, Payments $378,000 USD
Additional Paid in Capital $438,072,000 USD 39%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization $78,000 USD 28%
Deferred Tax Assets, Net of Valuation Allowance $1,738,000 USD 35%
Share-based Payment Arrangement, Expense $2,569,000 USD 12%
Preferred Stock, Par or Stated Value Per Share 0.001 USD/shares 0%